Azilsartan (Edarbi): a new ARB for treating hypertension

    loading  Checking for direct PDF access through Ovid

Abstract

Azilsartan medoxomil (Edarbi) is a new angiotensin-II receptor blocker for use in the treatment of hypertension. In our New products review, Steve Chaplin presents the clinical data relating to its efficacy and adverse events and Professor Gordon McInnes discusses its place in treatment.

Related Topics

    loading  Loading Related Articles